Healthcare has no borders. Neither should its financial infrastructure. 

Behind every healthcare innovation, medical device, biotech development and clinical trial that reaches its endpoint lies a cross-border financial infrastructure that must keep pace with the development around it. And, too often, it doesn’t. 

Pharmaceutical and biotech companies, medical device suppliers, CROs and pharmacies all operate across borders, coordinating suppliers, research sites and payments in multiple currencies at once. 

But as innovation speeds up, traditional financial systems remain disconnected, slow and complex. This hidden friction can stall growth, reduce liquidity and eat into profits. 

Where the real cost hides 

In healthcare, it often takes years to see value, but the capital is invested upfront. 

Let’s consider a clinical trial. A CRO managing a Phase II study may work with sites in several countries, paying investigators, hospitals and local vendors in their own currencies. This is common in emerging markets, where recruitment tends to be faster, and populations are larger. Every payment carries currency fluctuation and payment-delay risk. If a site payment is late, patient enrollment slows down. In clinical trials, time is more than money; it can mean the difference between delivering results on schedule and missing an entire funding cycle. 

Managing a healthcare business across borders means facing many financial risks, including: 

Supply chain costs make cross-border transactions expensive. Medical device suppliers and biotech manufacturers source specialist equipment and raw materials from overseas, increasingly from emerging-market suppliers who offer cost and capacity advantages but add currency and settlement complexity. This demands an enormous upfront capital commitment long before a product generates a single unit of revenue. 

Unhedged currency exposures can hit a clinical trial budget overnight on a shipment of imported parts between the time a purchase order is signed and when it is paid. For a pharmacy chain importing generic drugs, just a few percentage points lost to currency shifts across thousands of transactions can turn a high-growth quarter into a difficult one. 

And underneath it all is liquidity. When money is tied up in supply chains, inventory or trial operations, having enough liquid cash on hand matters as much as moving it efficiently. Pressure on working capital makes every other problem harder to manage. 

Why “high-tech” alone doesn’t solve it

To address these systemic challenges, healthcare businesses need to move away from rigid, traditional models and adopt more agile, flexible financial systems. Cross-border speed and scale demand robust technology. A modern platform should give a healthcare business real visibility across its global cash flows and a consolidated view that turns treasury from a reactive function into a strategic one. 

API integrations that connect payments and FX directly to existing financial systems can avoid manual reconciliation, reduce error rates and accelerate execution to match their scale. 

But technology is only half the equation. A dashboard cannot tell you whether a supplier payment will be delayed by local rules in an emerging market, or whether a currency pair is especially volatile. That insight is human, local and personal. 

Only a few payment specialists bring a full proposition under one roof. On one side, technology-led players focus on seamless cross-border payments. On the other, a few financial providers deliver high-touch, bespoke payments and FX solutions. 

What healthcare really needs 

The healthcare sector today demands access to a unified solution: technology-led payments combined with on-the-ground expertise, people who understand specific markets, regulatory nuances and the complexities of supply chains. The industry needs international payments, multicurrency accounts, currency risk management and access to working capital integrated on a single platform, powered by dedicated local expertise. 

For a biotech company handling high-volume global payments and collections, multicurrency accounts let companies manage currencies in one place and minimize brick-and-mortar accounts and the expensive costs associated with them. For a CRO exposed to multiple currencies, custom hedging solutions turn currency uncertainty into budget confidence, so market volatility does not impact margins and clinical trial costs. And for any organization with money tied up in its supply chain, access to financing keeps the business liquid while commercial schedules continue. 

Extensive currency coverage across major and emerging markets enables healthcare companies to reach hard-to-reach markets, where healthcare growth is heading and friction is greatest. 

Growth without borders 

Innovation, not borders, should drive healthcare growth. When cross-border money movement is seamless, fast, visible and reliable, healthcare organizations move faster, protect their margins and expand with confidence. 

Science has never respected borders. It’s time the financial infrastructure behind it caught up.